Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083602 | 0.91 | ESR1 (0.46) | ESR1TDP1ALDH1A1ESR2CYP2D6 | |
| SCHEMBL26999423 | 0.90 | MMP3 (0.58) | ESR1ESR2KMT2AMMP3BCL2L1 | |
| SCHEMBL193931 | 0.86 | CYP2D6 (0.48) | ALDH1A1CYP2D6KMT2ALMNACES2 | |
| Formic Acid SCHEMBL28298598 | 0.84 | CYP2D6 (0.48) | TDP1CYP2D6KMT2ALMNACES2 | |
| SCHEMBL1515879 | 0.82 | KYNU (0.42) | ESR1ALDH1A1ESR2CYP2D6GAA | |
| SCHEMBL26999424 | 0.81 | CYP1A2 (0.48) | ESR1ESR2CYP2D6KMT2A | |
| SCHEMBL26999421 | 0.81 | ALOX15 (0.54) | ESR1TDP1ALDH1A1ESR2CYP2D6 | |
| SCHEMBL26999419 | 0.81 | ESR1 (0.40) | IDO1TDO2ESR1TDP1ALDH1A1 | |
| SCHEMBL26999420 | 0.81 | MAPK1 (0.47) | ESR1TDP1ALDH1A1ESR2KMT2A | |
| SCHEMBL26999415 | 0.81 | ACHE (0.54) | ESR1TDP1ALDH1A1ESR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873315-B2 | Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2024-01-16 | — | — | US | disclosed |
| EP-1670485-A4 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP (CA) | 2009-03-11 | — | — | EP | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670485-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005034960-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | disclosed |
| US-4362878-A | DEVELOPMENT INHIBITOR RELEASE AGENTS | CIBA-GEIGY AG (CH) | 1982-12-07 | — | — | US | disclosed |
| US-4259437-A | EXCELLENT INTRA-IMAGE AND INTER-IMAGE EFFECTS OF EXCELLENT SPEED | CIBA-GEIGY AG (CH) | 1981-03-31 | — | — | US | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873315-B2 | Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts | ELANE, PNKP, SERPINB1 | IDO1 3053/4885TDO2 3321/4885ESR1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.